Obstetrics and Gynaecology - Theses

Permanent URI for this collection

Search Results

Now showing 1 - 2 of 2
  • Item
    Thumbnail Image
    Developing novel therapeutics for preeclampsia
    Brownfoot, Fiona ( 2016)
    Preeclampsia complicates 5-8% of pregnancies and is responsible for 60,000 maternal deaths and far greater numbers of perinatal deaths annually. Disappointingly these statistics have remained static over the last 50 years, owing to a lack of progress in developing clinical treatments. Excitingly, our field has made significant scientific advances in our understanding of the pathogenesis of preeclampsia in recent times. We now know that the preeclamptic placenta undergoes shallow invasion resulting in hypoxia, oxidative stress and inflammation that stimulate the release of two antiangiogenic factors, soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG), into the maternal bloodstream. These factors inflict widespread endothelial damage, which culminate in the clinical features of preeclampsia, predominately high blood pressure and proteinuria. Importantly, the discovery of sFlt-1 and sENG as pathogenic proteins of preeclampsia has identified specific targets which treatments can be developed against. The goal of therapies may be to reduce endothelial dysfunction and stabilise the maternal disease process. This would reduce preeclampsia disease progression and may equate to gestation prolongation and improved perinatal and maternal outcomes. To address this goal, this thesis has one overarching aim; to identify novel small molecules that can reduce placental sFtl-1 and sENG secretion and mitigate endothelial dysfunction. In particular, we have focused on re-purposing medications from other fields, as they have known safety profiles, and examine their effect on these key features of preeclampsia using primary human tissues. We identified four medications; statins, YC-1, metformin and sulfasalazine, and examined their effect on these key pathophysiological features of preeclampsia. We showed that all of these medications reduced sFlt-1 secretion from primary human placenta by decreasing transcription and reducing expression of its placental splice variant, sFlt-1 e15a. YC-1, metformin and sulfasalazine all reduced sENG secretion, with the later two likely exerting an effect by reducing expression of its transmembrane bound cleavage protease MMP 14. In contrast, endothelial secretion of sENG was increased by statins. All of these medications improved various features of endothelial dysfunction, examined in a range of functional assays. In undertaking this research, we have also uncovered new layers of molecular regulation of sFlt-1 and sENG. We found that pravastatin was exerting an effect on sFlt-1 by blocking the cholesterol synthesis enzyme HMG CoA reductase. Metformin was reducing sFlt-1 and sENG secretion likely by inhibiting the mitochondrial electron transport chain. Whilst sulfasalazine is known to up-regulate the anti-oxidant enzyme heme-oxygenase 1 and inhibit NFκB, we demonstrated that it was not exerting its effect on sFlt-1 through these mechanisms. In conclusion, this work has identified four candidate small molecule treatments for preeclampsia and provided insights into the mechanisms regulating the placental secretion of anti-angiogenic factors. It has opened several new avenues for future research. Hopefully, this body of work will lead to the development and translation of the first medical treatment for preeclampsia and reduce the devastating morbidity and mortality experienced by mothers and their babies.
  • Item
    Thumbnail Image
    Anti-angiogenic factors and pre-eclampsia: understanding disease pathophysiology for diagnostic and therapeutic translation
    PALMER, KIRSTEN ( 2014)
    Pre-eclampsia is a condition that complicates 3-8% of all pregnancies, inflicting significant maternal and neonatal morbidity and mortality worldwide, causing over 63,000 maternal deaths annually. In the 21st century these statistics continue unabated due to a lack of progress in clinical developments to improve pre-eclampsia diagnosis and treatment. Excitingly, scientific knowledge of the pathophysiological processes underlying pre-eclamptic development has advanced significantly in recent years. We now understand pre-eclampsia to arise from a two-stage process; beginning with abnormal placental development leading to persisting placental hypoxia, with subsequent placental release of anti-angiogenic factors causing widespread endothelial dysfunction. This endothelial dysfunction produces the clinical features of disease, namely hypertension and proteinuria. Importantly, the discovery of the anti-angiogenic proteins, soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), has presented new targets against which to develop potential therapeutic strategies to treat pre-eclampsia. The goal of such therapies would be to stabilise the maternal disease state to enable the pregnancy to progress to a gestation where delivery could occur with minimal risk to the infant. To address this goal, two aims provided the focus for the studies undertaken. Aim one sought to identify the molecular mechanisms underlying the development of pre-eclampsia with the goal of identifying new therapeutic targets, while aim two involved the development of antibodies targeting sFlt-1 and the exploration of their translational potential. This thesis details the studies performed to address these aims and their resulting findings in two parts, with each part addressing each of the aims respectively. In part one the final mechanisms of production of sFlt-1 and sEng from the placenta have been characterised for the first time. The identification that matrix metalloproteinase-14 cleaves membrane-bound endoglin on the placental surface, thereby releasing sEng into the maternal circulation, has identified a potentially new therapeutic target to prevent placental sEng release. Jumonji domain containing protein-6 has also been identified as regulating sFlt-1 production from placenta, significantly advancing our understanding of this pathway. Excitingly, jumonji domain containing protein-6 expression was also significantly reduced in pre-eclamptic placenta, being the first human condition linked to altered expression of this protein. Part two of this thesis saw the successful development of both polyclonal and monoclonal antibodies that target a placental specific sFlt-1 variant (sFlt-1 e15a) found predominately in humans. This variant could be the principle factor associated with pre-eclampsia. While exciting mRNA data exists in the literature, minimal work outlining the role of the protein exists. The development of these specific antibodies and their use in the creation of an enzyme linked immunosorbent assay has enabled for the first time the characterisation of this sFlt-1 variant in the maternal circulation of both normal and pre-eclamptic pregnancies. The translational potential for such antibodies as both diagnostic and therapeutic tools has been explored with encouraging preliminary findings. The significant findings resulting from this work not only advance pre-eclamptic scientific knowledge, but have also provided several new avenues for ongoing research. Improving outcomes for women and their babies afflicted with pre-eclampsia is now hopefully one step closer.